Skip to main content

Advertisement

SpringerLink
Log in

Evaluation of multiple serum markers in advanced melanoma

  • Research Article
  • Published:
Tumor Biology

Abstract

The aim of this retrospective study was to analyse in advanced melanoma the potential tumor markers S-100B, melanoma inhibiting activity protein (MIA) and YKL-40 compared to LDH. Serum levels of S-100B, MIA, LDH and YKL-40 were measured in 110 patients with advanced melanoma (36 in stage IIIB/C and 74 in stage IV), in 66 disease-free patients and in 65 healthy controls. Results show that S-100B, MIA and LDH levels were significantly higher in patients with advanced melanoma than in disease-free patients or healthy controls. The combination of S-100B plus MIA had the best diagnostic sensitivity, and the addition of LDH did not further increase this sensitivity. MIA was an independent prognostic factor of overall survival. Patients with both S-100B and MIA elevated had a significant shorter survival than those with both S-100B and MIA under the cut-off. YKL-40 levels did not differentiate patients with advanced melanoma from controls. We concluded that the combination of MIA plus S-100B showed a better prognostic value in advanced melanoma compared to LDH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Abbreviations

AJCC:

American Joint Committee on Cancer

MIA:

Melanoma inhibitory activity protein

AUC:

Area under curve

References

  1. Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Spatz A, Grob J-J, Malvehy J, Newton-Bishop J, Stratigos A, Pehamberger H, Eggermont A (2010) Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer 46:270–83

    Article  PubMed  Google Scholar 

  2. Brochez L, Naeyaert J-M (2000) Serological markers for melanoma. British J Dermatol 143:256–68

    Article  CAS  Google Scholar 

  3. Dummer R, Hauschild A, Guggenheim M, Jost L, Pentheroudakis G (2010) Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v194–7

    Article  PubMed  Google Scholar 

  4. Jennings L, Murphy GM (2009) Predicting outcome in melanoma: where are we now? Br J Dermatol 161:496–503

    Article  PubMed  CAS  Google Scholar 

  5. Balch CM, Buzaid AC, Soong S-J, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF (2001) Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J Clin Oncol 19:3635–48

    PubMed  CAS  Google Scholar 

  6. Marsden JR, Newton-Bishop JA, Burrows L, Cook M, Corrie PG, Cox NH, Gore ME, Lorigan P, MacKie R, Nathan P, Peach H, Powell B, Walker C (2010) Revised U.K. guidelines for the management of cutaneous melanoma 2010. Br J Dermatol 163:238–56

    Article  PubMed  CAS  Google Scholar 

  7. Kluger HM, Hoyt K, Bacchiocchi A, Mayer T, Kirsch J, Kluger Y, Sznol M, Ariyan S, Molinaro A, Halaban R (2011) Plasma markers for identifying patients with metastatic melanoma. Clin Cancer Res 17:2417–25

    Article  PubMed  CAS  Google Scholar 

  8. Miliotes G, Lyman GH, Cruse CW, Puleo C, Albertini PA, Rapaport D, Glass F, Fenske N, Soriano T, Cuny C, Van Voorhis N, Reintgen D (1996) Evaluation of new putative tumor markers for melanoma. Ann Surg Oncol 3:558–63

    Article  PubMed  CAS  Google Scholar 

  9. Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, Stolz W, Buettner R (1997) Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 57:3149–53

    PubMed  CAS  Google Scholar 

  10. Hsueh EC, Gupta RK, Glass EC, Yee R, Qi K, Morton DL (1998) Positron emission tomography plus serum TA90 immune complex assay for detection of occult metastatic melanoma. J Am Coll Surg 187:191–7

    Article  PubMed  CAS  Google Scholar 

  11. Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der Maase H (2006) Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer 106:1130–9

    Article  PubMed  CAS  Google Scholar 

  12. Abraha HD, Fuller LC, Du Vivier AW, Higgins EM, Sherwood RA (1997) Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma. Br J Dermatol 137:381–5

    Article  PubMed  CAS  Google Scholar 

  13. Gogas H, Eggermont AMM, Hauschild A, Hersey P, Mohr P, Schadendorf D, Spatz A, Dummer R (2009) Biomarkers in melanoma. Ann Oncol 20:vi8–13

    Article  PubMed  Google Scholar 

  14. Harpio R, Einarsson R (2004) S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin Biochem 37:512–8

    Article  PubMed  CAS  Google Scholar 

  15. Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW (2008) Immunohistochemical characteristics of melanoma. J Cutan Pathol 35:433–44

    Article  PubMed  Google Scholar 

  16. Bosserhoff AK, Hein Rd, Bogdahn U, Buettner R (1996) Structure and promoter analysis of the gene encoding the human melanoma-inhibiting protein MIA. J Biol Chem 271:490–5

    Article  PubMed  CAS  Google Scholar 

  17. Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA (2006) Serum YKL-40, A New prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 15:194–202

    Article  PubMed  CAS  Google Scholar 

  18. Krause S, Rehli M, Kreutz M, Schwarzfischer L, Paulauskis J, Andreesen R (1996) Differential screening identifies genetic markers of monocyte to macrophage maturation. J Leukocyte Biol 60:540–5

    PubMed  CAS  Google Scholar 

  19. Peltomaa R, Paimela L, Harvey S, Helve T, Leirisalo-Repo M (2001) Increased level of YKL-40 in sera from patients with early rheumatoid arthritis: a new marker for disease activity. Rheumatol Int 20:192–6

    Article  PubMed  CAS  Google Scholar 

  20. Shackelton LM, Mann DM, Millis AJ (1995) Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J Biol Chem 270:13076–83

    Article  PubMed  CAS  Google Scholar 

  21. Johansen JS, Bojesen SE, Tybjaerg-Hansen A, Mylin AK, Price PA, Nordestgaard BG (2010) Plasma YKL-40 and total and disease-specific mortality in the general population. Clin Chem 56:1580–91

    Article  PubMed  CAS  Google Scholar 

  22. Johansen JS, Jensen BV, Roslind A, Price PA (2007) Is YKL-40 a new therapeutic target in cancer? Expert Opin Ther Targets 11:219–34

    Article  PubMed  CAS  Google Scholar 

  23. Deichmann M, Benner A, Bock M, Jackel A, Uhl K, Waldmann V, Naher H (1999) S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 17:1891–6

    PubMed  CAS  Google Scholar 

  24. Cao MG, Auge JM, Molina R, Marti R, Carrera C, Castel T, Vilella R, Conill C, Sanchez M, Malvehy J, Puig S (2007) Melanoma inhibiting activity protein (MIA), beta-2 microglobulin and lactate dehydrogenase (LDH) in metastatic melanoma. Anticancer Res 27:595–9

    PubMed  CAS  Google Scholar 

  25. Garnier JP, Letellier S, Cassinat B, Lebbé C, Kerob D, Baccard M, Morel P, Basset-Seguin N, Dubertret L, Bousquet B, Stoitchkov K, Bricon TL (2007) Clinical value of combined determination of plasma l-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma. Eur J Cancer 43:816–21

    Article  PubMed  CAS  Google Scholar 

  26. Egberts F, Pollex A, Egberts JH, Kaehler KC, Weichenthal M, Hauschild A (2008) Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH. Onkologie 31:380–4

    Article  PubMed  CAS  Google Scholar 

  27. Dummer R, Panizzon R, Bloch PH, Burg G (2005) Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology 210:39–44

    Article  PubMed  CAS  Google Scholar 

  28. Garbe C, Schadendorf D, Stolz W, Volkenandt M, Reinhold U, Kortmann RD, Kettelhack C, Frerich B, Keilholz U, Dummer R, Sebastian G, Tilgen W, Schuler G, Mackensen A, Kaufmann R, Hauschild A (2008) Short German guidelines: malignant melanoma. J Dtsch Dermatol Ges 6:S9–14

    Article  PubMed  Google Scholar 

  29. Krahn G, Kaskel P, Sander S, Waizenhofer PJ, Wortmann S, Leiter U, Peter RU (2001) S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastasis compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res 21:1311–6

    PubMed  CAS  Google Scholar 

  30. Garbe C, Leiter U, Ellwanger U, Blaheta H-J, Meier F, Rassner G, Schittek B (2003) Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer 97:1737–45

    Article  PubMed  CAS  Google Scholar 

  31. Faries MB, Gupta RK, Ye X, Lee C, Yee R, Leopoldo Z, Essner R, Foshag LJ, Elashoff D, Morton DL (2007) A comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients. Cancer Investigation 25:285–93

    Article  PubMed  CAS  Google Scholar 

  32. Hauschild A, Engel G, Brenner W, Glaser R, Monig H, Henze E, Christophers E (1999) S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 56:338–44

    Article  PubMed  CAS  Google Scholar 

  33. Auge JM, Molina R, Filella X, Bosch E, Cao MG, Puig S, Malvehy J, Castel T, Ballesta AM (2005) S-100B and MIA in advanced melanoma in relation to prognostic factors. Anticancer Res 25:1779–82

    PubMed  CAS  Google Scholar 

  34. Johansen JS (2006) Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 53:172–209

    PubMed  CAS  Google Scholar 

  35. Siekmann L, Bonora R, Burtis CA, Ceriotti F, Clerc-Renaud P, Ferard G, Ferrero CA, Forest JC, Franck PF, Gella FJ, Hoelzel W, Jorgensen PJ, Kanno T, Kessner A, Klauke R, Kristiansen N, Lessinger JM, Linsinger TP, Misaki H, Mueller MM, Panteghini M, Pauwels J, Schiele F, Schimmel HG, Vialle A, Weidemann G, Schumann G (2002) IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. International Federation of Clinical Chemistry and Laboratory Medicine. Part 7. Certification of four reference materials for the determination of enzymatic activity of gamma-glutamyltransferase, lactate dehydrogenase, alanine aminotransferase and creatine kinase accord. Clin Chem Lab Med 40:739–45

    Article  PubMed  CAS  Google Scholar 

  36. Kruijff S, Bastiaannet E, Kobold AC, van Ginkel RJ, Suurmeijer AJ, Hoekstra HJ (2009) S-100B concentrations predict disease-free survival in stage III melanoma patients. Ann Surg Oncol 16:3455–62

    Article  PubMed  CAS  Google Scholar 

  37. Hofmann MA, Gussmann F, Fritsche A, Biesold S, Schicke B, Kuchler I, Voit C, Trefzer U (2009) Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma. Melanoma Res 19:17–23

    Article  PubMed  CAS  Google Scholar 

  38. Tarhini AA, Stuckert J, Lee S, Sander C, Kirkwood JM (2009) Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol 27:38–44

    Article  PubMed  Google Scholar 

Download references

Acknowledgement

A.D.L is funded by the Xunta de Galicia through a research-staff contract “Angeles Alvariño”.

Author information

Authors and Affiliations

  1. Laboratory of Biochemistry, University Clinic of Navarra, Avd. Pio XII 36, Pamplona, 31008, Spain

    Angel Díaz-Lagares, Estíbaliz Alegre, Ainhoa Arroyo & Alvaro González

  2. Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, Spain

    Angel Díaz-Lagares

  3. Department of Medical Oncology, University Clinic of Navarra, Pamplona, Spain

    Maria E. Zudaire & Salvador Martín-Algarra

  4. Medical Oncology Department, Instituto Oncológico Dr Rosell—Pangaea Biotech, Instituto Universitari Dexeus, Barcelona, Spain

    María González-Cao & Santiago Viteri

Authors
  1. Angel Díaz-Lagares
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Estíbaliz Alegre
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ainhoa Arroyo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. María González-Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maria E. Zudaire
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Santiago Viteri
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Salvador Martín-Algarra
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Alvaro González
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alvaro González.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Díaz-Lagares, A., Alegre, E., Arroyo, A. et al. Evaluation of multiple serum markers in advanced melanoma. Tumor Biol. 32, 1155–1161 (2011). https://doi.org/10.1007/s13277-011-0218-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-011-0218-x

Keywords

Search

Navigation